Peptide vaccine for treatment of IDH1 R132H mutant-positive cancers (P-987)

Key facts
- Peptide consisting of between 10-20 amino acids identical to human isocitrate dehydrogenase type 1 (IDH1) including an exchange of amino acid at position 132 from R to H.
- Peptide for diagnosis of IDH1 R132H mutation in patients suffering from various types of cancer without the need for biopsy
- Peptide for therapeutic vaccination and subsequent immune monitoring of patients with various types of cancer containing an IDH1 R132H mutation

Abstract
Mutations in the human isocitrate dehydrogenase type 1 (IDH1) gene affecting position 132 (R132H) were originally detected in glioma. Since these types of brain tumors, accompanied by IDH1 R132H mutation, are usually aggressive and associated with a poor prognosis, effective therapies and proper diagnostic tools are urgently needed in clinical practice. State of the art diagnosis of IDH1 R132H mutation in cancer requires tissue samples, which are obtainable only via cumbersome and potentially dangerous biopsy.

Applications and Commercial Opportunity
Diagnosis of IDH1 R132H mutation in tumor cells without the need for biopsy. In addition the peptide can be used for therapeutic vaccination and subsequent immune monitoring.

Inventors
The invention was jointly conceived by Prof. Platten M., Schumacher T. and Prof. Wick W., University of Heidelberg and DKFZ Heidelberg, Germany

Scientific Publications


Intellectual Property

DKFZ Contact:
Dr. Frieder Kern
Deutsches Krebsforschungszentrum
Technology Transfer Office T010
Email: f.kern@dkfz.de
Tel.: +49-(0)6221-42-2952
Fax: +49-(0)6221-42-2956